UK cost agency says 'no' to Bayer prostate cancer drug Xofigo
LONDON (Reuters) - Britain's healthcare cost agency has recommended against using Bayer's new prostate cancer drug Xofigo on the state health service because the German firm did not provide evidence on how well it worked compared to other therapies.
The draft guidance from the National Institute for Health and Care Excellence (NICE), issued on Monday, is now subject to consultation.
"We are disappointed not to able to recommend this drug, but we have to be confident that its benefits justify its considerable cost," said NICE Chief Executive Andrew Dillon.
Xofigo - priced at an average 24,240 pounds ($40,000) for a course of treatment but also eligible for an undisclosed discount - is a radioactive agent that migrates to parts of the body with abnormal bone growth.
Bayer clinched a $2.9 billion deal last month to acquire Norway's Algeta in order to gain full control of the treatment, which the two companies developed jointly. ($1 = 0.6057 British Pounds)
(Reporting by Ben Hirschler; Editing by Elaine Hardcastle)
- Obama condemns killing of reporter, U.S. hits militants in Iraq |
- Gaza war rages on, Hamas says Israel tried to kill its military chief |
- Four beheaded corpses found in Egypt's Sinai: security sources
- Father of Texas 'affluenza' teen arrested for impersonating police officer
- Islamic State opens new anti-U.S. front with beheading video
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video